COSM: COSM: C‑Sept PRO gains traction in Greek hospitals; annualized sales >$1.3M at ~72% gross margin

AI Summary

Cosmos Health (NASDAQ: COSM) said its C-Sept PRO antiseptic has accelerated adoption across major Greek public and private hospitals, with average monthly sales >$93k over six months and >$108k over the last three months, putting annualized sales above $1.3M and implying roughly $0.9M in annualized gross profit at ~72% gross margin. The company cites repeat ordering and participation in public hospital tenders as demand drivers and intends to scale the hospital antiseptics business further in Greece and eventually into other European markets using its EU GMP manufacturing platform.

Positives

Average monthly sales >$93k (six‑month) and >$108k (three‑month), implying annualized sales >$1.3M
High reported gross margin of ~72%, implying ~ $0.9M annualized gross profit
Adoption and repeat orders from major Greek public and private hospital groups; participating in public tenders

Negatives

Reported sales figures are annualized projections based on recent months, not guaranteed
Current commercial traction is concentrated in Greece; European expansion is planned but not yet executed
Absolute revenue remains modest (~$1.3M annualized) relative to broader commercial scale